event,time
62 years old ,0
    male ,0
    admitted to the hospital ,0
    dyspnea ,0
    cough ,0
    body condition loss ,0
    non-small cell lung cancer ,-672
    no oncogenic mutations ,0
    high PD-L1 expression at 80% ,0
    tumor mass para-hilar ,0
    extended to the right upper lobe and middle lobe ,0
    partially necrotic ,0
    bilateral necrotic adrenal metastases ,0
    no other metastatic lesion ,0
    hypertension ,0
    chronic obstructive pulmonary disease ,0
    peripheral arterial disease ,0
    preserved general health status ,0
    no organ failure ,0
    survival estimated well beyond 3 months ,0
    exertional dyspnea (mMRC scale 3) ,0
    productive cough ,0
    difficulty in expectoration ,0
    no need for oxygen support ,0
    decrease in right apical vesicular lung sound ,0
    painless palpable mass in the right hypochondrium ,0
    no sign of peripheral hypoperfusion ,0
    bronchial fibroscopy ,0
    complete upper right lobe atelectasis ,0
    wild-type Streptococcus pneumoniae from bronchoaspiration ,-48
    start amoxicillin-clavulanic acid ,-48
    fever (up to 39.3 Â°C) ,-168
    chills ,-168
    new fibroscopy ,-168
    blood culture samples collected ,-168
    leukocyte count increased from 13.5 G/L to 24 G/L ,-168
    seven blood culture samples collected ,-168
    anaerobic blood bottle culture positive ,-168
    Gram-positive coccobacilli observed ,-168
    continue amoxicillin-clavulanic acid ,-168
    central venous catheter placed ,-96
    first chemo-immunotherapy cycle (Carboplatin-Pemetrexed-Pembrolizumab) ,-72
    granulocyte colony-stimulating factor for 5 days ,-72
    no identification using MALDI-TOF MS ,-72
    Catabacter hongkongensis identified ,-72
    respiratory status declined ,24
    oxygen flow rate of 1 L/min needed ,24
    hypotensive (blood pressure 89/59 mmHg) ,24
    oliguria ,24
    poor peripheral perfusion ,24
    hyperlactatemia (4.1 mmol/L) ,24
    vascular filling (500 mL of saline solution) ,24
    start piperacillin-tazobactam and amikacin ,24
    transfer to Intensive Care Unit ,24
    vasopressive support ,24
    piperacillin-tazobactam continued until the 21st/01 ,24
    clinical condition stable ,24
    septic shock 23 days after ,360
    no other bacteria isolated ,360
    blood culture samples pairs collected ,360
    urine cultures ,360
    BAL ,360
    blood sample positive for Staphylococcus haemolyticus ,360
    switch to imipenem/cilastatin ,360
    death ,648
